DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 31, 2006--Elan Corporation, plc today announced its fourth quarter and full-year 2005 financial results and provided guidance for its financial outlook for 2006. Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said, “2005 was a year of unexpected challenges, business opportunity and scientific progress. Operating and financial discipline combined with selective investments in our science and technology allowed us to make advancements in all areas of the company. Progress towards the potential re-marketing of Tysabri, further developments in the immunotherapeutic program for Alzheimer’s and growth within our Drug Technology business further demonstrate our commitment to delivering tangible results through a relentless focus on the execution of our plans.”
